Evidence map›Paper›PMID 39907859›Full record

ArticleBiotechnology letters2025

Bacillus velezensis CE 100 controls anthracnose disease in walnut trees (Juglans regia L.) by inhibiting Colletotrichum gloeosporioides and eliciting induced systemic resistance.

Vantha Choub, Sang-Jae Won, Jae-Hyun Moon, Su-In Choi, Henry B Ajuna, Young Sang Ahn

Abstract read
PubMed Publisher
In one paragraph

Article in Biotechnology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. The chemical blueprint of Trichoderma for next-generation microbial biostimulants.Metabolomics : Official journal of the Metabolomic Society · 2026
    Article
  2. Identification of the Biocontrol Effect ofJournal of fungi (Basel, Switzerland) · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Vantha Choub *Department of Forest Resources, College of Agriculture and Life Sciences, Chonnam National University, Gwangju, 61186, Korea.
Sang-Jae Won *Department of Forest Resources, College of Agriculture and Life Sciences, Chonnam National University, Gwangju, 61186, Korea.
Jae-Hyun MoonDepartment of Forest Resources, College of Agriculture and Life Sciences, Chonnam National University, Gwangju, 61186, Korea.
Su-In ChoiDepartment of Forest Resources, College of Agriculture and Life Sciences, Chonnam National University, Gwangju, 61186, Korea.
Henry B AjunaDepartment of Forest Resources, College of Agriculture and Life Sciences, Chonnam National University, Gwangju, 61186, Korea.
Young Sang AhnDepartment of Forest Resources, College of Agriculture and Life Sciences, Chonnam National University, Gwangju, 61186, Korea. ysahn@jnu.ac.kr.ORCID http://orcid.org/0000-0002-3181-8919

Funding

Forest Service RS-2024-00405196Ministry of Education 2021RIS-002
6 · The paper itself

Abstract

Biological control of plant diseases is recognized as an effective and environmental friendly alternative to chemical fungicides. We demonstrated the dual biocontrol strategy of Bacillus velezensis CE 100 through the hydrolytic activity of chitinase and β-1,3-glucanase and the elicitation of induced systemic resistance (ISR) against Colletotrichum gloeosporioides that causes anthracnose disease in walnut trees. B. velezensis CE 100 produced a maximum of 62.1 units mL

Indexed as

BacillusColletotrichumDisease ResistanceJuglansPlant DiseasesChitinasesGlucan 1,3-beta-GlucosidasePlant Systemic Acquired ResistanceChitinasesGlucan 1,3-beta-GlucosidaseChitinaseIndole-3-acetic acid productionInduced systemic resistanceMycelial inhibitionPathogenic fungiPlant growth promotionSpore germinationβ-1,3-glucanase

Identifiers

PMID39907859

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.